Passage Bio to Present at 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Expands Executive Management Team
July 25, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, July 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Announces New Dedicated Gene Therapy Manufacturing Suite
July 10, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, July 10, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala
May 30, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, May 30, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
Passage Bio to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, May 29, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Appoints Saqib Islam to Board of Directors
March 28, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, March 28, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases,...
Passage Bio to Present at the Cowen and Company 39th Annual Health Care Conference
March 05, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, March 05, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases,...
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
February 14, 2019 08:00 ET
|
Passage Bio
PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant...